Oncolytics Biotech ONCY has observed the following analyst ratings within the last quarter:  These 4 analysts have an average price target of $11.0 versus the current price of Oncolytics Biotech at $1.75, implying  upside. Below is a summary of how these 4 analysts rated Oncolytics Biotech over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock  This average price target has increased by 83.33% over the past month. Stay up to date on Oncolytics Biotech analyst ratings. If you are interested in following small-cap stock news and performance you can start by tracking it here. Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter. Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors. If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro. This article was generated by Benzinga's automated content engine and reviewed by an editor. Â© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Join Benzinga Edge and unlock all the major upgrades, downgrades, and changes to the market's most accurate analysts. Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.